In the majority of prospective clinical studies, at-risk subjects were not extensively tested in early age prior to the symptoms, and most screening studies focused on the measurement of TG2 autoantibodies to detect transient or persistent autoimmunity, and manifest CeD [18,19]. Here, TGM2 is linked to cranioectodermal dysplasia.